期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

在心血管疾病治疗中抑制肾素-血管紧张素-醛固酮系统药物的联合应用 被引量：2

Combined use of drugs inhibiting rennin-angiotensin-aldosterone system in treatment of cardiovascular diseases
原文传递
导出
摘要 抑制肾素-血管紧张素-醛固酮系统(RAAS)药物在心血管疾病的预防和治疗中发挥重要作用。联合应用血管紧张素转化酶抑制药(ACEI)和血管紧张素Ⅱ受体拮抗药(ARB)主要用于蛋白尿、RAAS抑制不完全的心力衰竭。联合应用醛固酮抑制剂和ACEI或ARB可降低心力衰竭患者的死亡率。尚需对联合应用肾素抑制药和其他RAAS抑制药做进一步研究。 The drugs that inhibit rennin-angiotensin-aldosterone system （RAAS） play important roles in the prevention and treatment of cardiovascular diseases. The combination use of angiotensin convering enzyme inhibitors （ACEI） and angiotensin Ⅱ receptor antagonist （ARB） is mainly used in proteinuria and heart failure with incomplete RAAS block. The combination use of ACEI or ARB and aldosterone inhibitor may decrease the mortality of heart failure patients. The studies for combination use of rennin inhibitor and other RAAS inhibitor are still needed.
作者 黄震华
机构地区 上海交通大学医学院附属第九人民医院心血管病研究室
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2012年第11期643-647,共5页 Chinese Journal of New Drugs and Clinical Remedies
关键词 肾素-血管紧张素系统 醛固酮 心力衰竭 治疗 rennin-angiotensin system aldosterone heart failure therapy
分类号 R972 [医药卫生—药品]
  • 相关文献

参考文献26

  • 1STECKELINGS UM, RETI'IG R, UNGER T. Angiotensin in the kidney: a key to understanding hypertension? [J]. Cell Metab, 2007, 5(1): 7-8.
  • 2UNGER T, STOPPELHAAR M. Rational for double rennin- angiotensin-aldosterone system blockade[J]. Am J Cardiol, 2007, 100(3A) : 25J-31J.
  • 3DOULTON TW, HE FJ, MACGREGOR GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension [J]. Hypertension, 2005, 45(5): 880-886.
  • 4MVMURRAY JJV, OSTERGREN J, SWEDBERG K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin- converting- enzyme inhibitors: the CHARM- Added trial[J]. Lancet, 2003, 362(9386): 767-771.
  • 5YUSUF S, OFEFFER MA, SWEDBERG K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial[J]. Lancet, 2003, 362(9386): 777-781.
  • 6KRUM H, CARSON P, FARSANG C, et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from VaI-HeFT[J]. Eur J Heart Fail, 2004, 6(7) : 937-945.
  • 7MCKELVIE RS, YUSUF S, PERICAK D, et ol. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators[J]. Circulation, 1999, 100(10): 1056-1064.
  • 8SOLOMON SD, SKAL1 H, ANAVEKAR NS, et at. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction[J]. Circulation, 2005, 111(25): 3411-3419.
  • 9YUSUF S, TEO KK, POGUE J, et ol. Telmisartan, ramipril, or both in patients at high risk for vascular events [J]. N Engl J Med, 2008, 358(15): 1547-1559.
  • 10MANN JF, SCHMIEDER RE, MCQUEEN M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study) : a multicentre, randomised, double-blind, controlled trial[J]. Lancet, 2008, 372 (9638) : 547-553.

同被引文献10

引证文献2

二级引证文献5

中国新药与临床杂志
2012年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部